There is no complete curative therapy against chronic hepatitis B virus (HBV) infection, however, about 10% of these patients are treated by antiviral drugs to control HBV replication and further progression of liver damages. Treatment-related benefit is found in about one-third of these patients. However, patients with chronic HBV infection must be properly evaluated before starting antiviral therapy to design the therapeutic regimen. Moreover, these patients should be closely monitored for indefinite periods because they may develop serious and life-threatening complications. Till now, antiviral drugs have mainly been used in developed and rich countries; these drugs will be popularized in developing countries in the near future. This is because comparatively cheaper and oral antiviral drugs are now commercially available. However, thorough understanding about medical infrastructures and investigation facilities should be considered before these drugs are widely used in patients with chronic HBV infection in the developing countries. We would discuss about the expectations of chronic HBV carriers of developing nations in the context of availability of comparatively cheaper and orally-consumable antiviral drugs. Next, we will provide outlines about the factors those should be well addressed to have beneficial effects of antiviral drugs in chronic HBV carriers in developing countries.